Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. Canceled.

2. Canceled.

3. (Currently amended) A method of treating~~, managing or preventing a disease associated with undesired angiogenesis~~ chronic uveitis, which comprises administering to a patient in need of such treatment~~, management or prevention~~ a therapeutically ~~or prophylactically~~ effective amount of cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide, which has the following structure:



or a pharmaceutically acceptable salt, or solvate thereof.

4. (Currently amended) A method of treating~~, managing or preventing a disease associated with undesired angiogenesis~~ chronic uveitis, which comprises administering to a patient in need of such treatment~~, management or prevention~~ a therapeutically ~~or prophylactically~~ effective amount of cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide, which has the following structure:



or a pharmaceutically acceptable salt, or solvate thereof, and a therapeutically ~~or prophylactically~~ effective amount of a second active ingredient.

5. Canceled.

6. Canceled.

7. Canceled.

8. (Previously presented) The method of claim 4, wherein the second active ingredient is hematopoietic growth factor, cytokine, anti-cancer agent, antibiotic, cox-2 inhibitor, immunomodulatory agent, immunosuppressive agent, corticosteroid, or a pharmacologically active mutant or derivative thereof, or a combination thereof.

9. (Previously presented) The method of claim 8, wherein the second active ingredient is oblimersen, melphalan, G-CSF, GM-CSF, EPO, topotecan, pentoxifylline, taxotere, irinotecan, a COX-2 inhibitor, ciprofloxacin, dexamethasone, doxorubicin, vincristine, IL 2, IFN, dacarbazine, Ara-C, vinorelbine, isotretinoin, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or a pharmacologically active mutant or derivative thereof, or a combination thereof.

10. Canceled.

11. (Previously presented) The method of claim 3 or 4, wherein the compound is enantiomerically pure.

12 – 24. Canceled.

25. (Previously presented) The method according to claim 3 or 4, wherein the compound is administered in an amount of from about 1 to about 10,000 mg per day.

26 – 32. Canceled.

33. (New) The method of claim 25, wherein the compound is administered in an amount of about 10, 25, 50, 100, 200 or 300 mg per day.

34. (New) The method of claim 25, wherein the compound is orally administered.

35. (New) The method of claim 25, wherein the compound is administered in a capsule.

36. (New) The method of claim 35, wherein the compound is administered in 50 mg or 100 mg of a capsule.

37. (New) The method of claim 25, wherein the compound is topically administered.

38. (New) The method of claim 37, wherein the compound is administered in a spray, aerosol, solution, suspension or eye drop.

39. (New) The method of claim 8, wherein the second active ingredient is prednisone.